RESEARCH

Open Access

The validity and reliability of Indonesian version of atrial fibrillation effect on quality of life (AFEQT) questionnaire for atrial fibrillation patients



Putri Zulmiyusrini¹, Muhammad Yamin^{2*}, Muhadi Muhadi², Juferdy Kurniawan³ and Simon Salim²

Abstract

Background More than 60% of patients with atrial fibrillation (AF) have a significant health-related quality of life (HRQoL) impairment. HRQoL, a patient-reported outcome (PRO), has become an important endpoint to assess treatment success in AF patients. The Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire is an AF-specific HRQoL tool shown to be feasible, reliable, and valid, with translations in various languages. Since this questionnaire has never been translated or validated in Indonesian, we aimed to determine the validity and reliability of the Indonesian version of the AFEQT questionnaire for AF patients.

Results This cross-sectional, observational study was conducted in the Integrated Cardiovascular Service Polyclinic, Cipto Mangunkusumo Hospital, Indonesia, from December 2021 to March 2022. A total of 30 participants were recruited for cross-cultural adaptation process, which consisted of translation and adaptation process, and a total of 102 participants were consecutively recruited to participate in the validation process, which consisted of validity test (construct validity) and reliability tests (internal consistency and test-retest). The retest was conducted within a 1–2-week interval after the baseline assessment, by analyzing the intraclass correlation coefficient (ICC). The construct validity was determined by multitrait scaling analysis, and the convergent and divergent validity was compared to SF-36 domains. Multitrait scaling analysis revealed that all items in the Indonesian version of the AFEQT questionnaire had a strong negative correlation towards their respective domains (r -0.639–-0.960). For convergent and divergent validity, AFEQT domains had weak to strong positive correlations to all SF-36 domains (r 0.338–0.693). This questionnaire also had acceptable internal consistency (Cronbach's α for overall score: 0.947; Domains: Symptoms: 0.818, Daily Activities: 0.943, Treatment Concern: 0.894, and Treatment Satisfaction: 0.865), as well as moderate-to-good test-retest reliability (0.521–0.828).

Conclusions The Indonesian version of the AFEQT questionnaire has good validity and reliability for assessing quality of life of atrial fibrillation patients in Indonesia.

Keywords Atrial fibrillation, Quality of life, AFEQT, Questionnaire, Validation

*Correspondence: Muhammad Yamin yamin@ui.ac.id

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Introduction

Atrial fibrillation (AF) is the most common arrhythmia in adults and the leading cause of stroke, heart failure, sudden death, and cardiovascular morbidity worldwide. AF prevalence is increasing globally, with current estimates at 2-4% in adults. Greater prevalence is found in older persons and patients with other comorbidities, such as hypertension, diabetes mellitus, heart failure (HF), coronary artery disease (CAD), chronic kidney disease (CKD), obesity, and obstructive sleep apnea (OSA) [1]. The prevalence rate in Southeast Asia shows a similar trend, such as Singapore at 1.5%, Thailand at 0.4-2.2%, and Malaysia at 0.5–0.7%, which are relatively lower than that of other countries [2]. In Indonesia, no recent epidemiological study of AF has been performed nationally, to the best of our knowledge. A multinational observational study, the Monitoring of Trend and Determinant in Cardiovascular Disease (MONICA), was conducted on the urban population in Jakarta in 1998 and found that the incidence of AF was 0.2%, with a male-to-female ratio of 3:2 [3]. A more recent study conducted in Makassar in 2014–2018 reported an AF prevalence of 0.96% [4].

Patients with AF are at risk of stroke and experience various symptoms, such as lethargy, palpitations, dyspnea, and chest tightness, all of which decrease health-related quality of life (HRQoL) and place a significant burden on patients, public health systems, and the health economy [1, 5]. More than 60% of AF patients have a significant quality of life (QoL) impairment. QoL is significantly lower in women, young individuals, and patients with comorbidities. The reduction of QoL is associated with a high risk of hospitalization [6]. Therefore, QoL is an important cardiovascular health outcome in clinical practice.

QoL is subjective and defined as a perception of discrepancy between actual and desired functional status and the overall impact of disease on the well-being of a given patient [7]. QoL is a type of Patient-Reported Outcome (PRO) and a subject of interest as an endpoint in clinical trials to improve care and assess treatment success from the patient's perspective [5]. QoL can now be quantified using a validated general and disease-specific assessment tool. More than 10 AF-specific QoL tools have been validated to assess QoL in patients with AF. Compared to other AF-specific instruments, the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire has the best psychometric properties. It explicitly measures patients' perceptions of their symptoms, functional impairment, treatment concerns, and satisfaction with treatment [9]. It has been used in various QoL studies in AF patients and has been translated and validated into 24 languages, including Chinese, Greek, Russian, and Turkish [10-14]. Translations of the AFEQT into other languages showed highly comparable psychometric properties to the original version of the AFEQT, which was used in the US and Canada [9]. Indonesia, the fourth largest country in the world and with increasing life expectancy, has been noted for its increasing AF prevalence. To date, there is no Indonesian version of any AFspecific QoL questionnaire. Therefore, a culturally and linguistically relevant instrument to assess QoL for AF patients in Indonesia is essential.

To address the need for a comprehensive measure of self-reported AF outcomes, a translation and cultural adaptation process must be conducted. A Translation and Cultural Adaptation (TCA) group was formed by The Professional Society for Health Economics and Outcomes Research (ISPOR) in 1999 to create guidelines for the translation and cultural adaptation of PROs. The group reviewed several guidelines available for translation and cultural adaptation and summarized the translation process into ten steps (preparation, forward translation, reconciliation, back translation, back translation review, harmonization, cognitive debriefing, review of cognitive debriefing results and finalization, proofreading, and final report) [15]. However, in this study, we used the cross-cultural adaptation guideline from Beaton and Guillemin, which consists of 6 stages (translation, synthesis, back translation, expert committee review, test of the prefinal version, and submission of documentation to the committee) to translate and validate the AFEQT questionnaire among Indonesian AF patients, as our team was more familiar with and had previously used it for translating the SF-36 and AQUAREL questionnaires into the Indonesian language [16-19].

Methods

Setting and study design

This cross-sectional, observational study with consecutive sampling and a survey method of data collection was conducted in the Integrated Cardiovascular Service Polyclinic in Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia, over a period of 4 months from December 2021 to March 2022.

Study population

Eligible subjects were Indonesian-speaking outpatients, 18 years or older, with documented paroxysmal, persistent, longstanding persistent, or permanent AF who were willing to participate in this study. Patients were invited to participate at the time of their scheduled clinic or procedural visit, and those who joined provided written informed consent. Patients with cognitive impairment or active psychiatric illnesses, physical disabilities (handicaps) that interfered with their ability to fill the questionnaire, as well as those treated or hospitalized for severe acute or chronic conditions or who underwent cardiac surgery within 30 days of the recruitment time were excluded from the study. A total of 30 participants were recruited for cross-cultural adaptation, based on minimal requirement sample in the guidelines by Beaton et al. [16]. A total of 102 participants were consecutively recruited for the validity study based on minimum of 100 participants required to fulfil a ratio of 5 participants to each item of the AFEQT questionnaire.

Study instruments

Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire.

The 20-item AFEQT questionnaire was developed and validated by Spertus et al. [9] to assess the impact of AF and its treatment on patient symptoms, functioning, and daily activities through the following four domains: Symptoms (4 items), Daily Activities (8 items), Treatment Concern (6 items), and Treatment Satisfaction (2 items) [9]. It was developed as a self-administered instrument, using a 4-week recall frame, with all items rated on a 7-point Likert scale. The Likert responses ranged from no limitations/symptoms [1] to the most severe limitations/symptoms [7] in each domain. Only three domains (Symptoms, Daily Activities, and Treatment Concerns) were included in the overall score calculation, indicating the patient's quality of life. The two items in the Treatment Satisfaction domain were not included in the overall score, as they did not assess patients' health status. The raw score of 1 to 7 in the overall and domain scores were transformed to a scale of 0 to 100. Higher scores indicate better health status or QoL overall and for each domain. The scoring manual was provided in the supplementary material. We obtained permission via licensing from SJM/Abbott to use the questionnaire and its content.

SF-36

The 36-item Short Form Health Survey is well-validated, reliable, and the most commonly used general health status measure. It has also been widely used in various studies to assess the AF patients' quality of life [20-25]. Many studies have addressed the content, construct, concurrent, and predictive value of SF-36. Systematic comparisons indicate that SF-36 includes eight most frequently represented health concepts. Reliability statistics have exceeded the minimum standard of 0.70 in group comparison. The SF-36 questionnaire consists of 8 domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH) [26]. Mental (MCS) and Physical (PCS) Component Summary scores are generated to make it possible to reduce the number of statistical comparisons (from eight to two) in analyzing between the SF-36 physical and mental health outcomes. A four-week recall period with a variety response scale is used, with higher scores indicating better health status. Since the weights vary among items, the score item should be recoded into a range of 0-100, where 0 represents the lowest score and 100 represents the highest. The scoring instruction can be accessed from the RAND website [27]. The Indonesian Version of SF-36 has been validated in pacemaker patients and shown to have acceptable internal consistency and test-retest reliability [18].

Study procedures

This study followed the cross-cultural adaptation guidelines by Beaton et al., which consists of 6 stages (translation, synthesis, back translation, expert committee review, test of the prefinal version, and submission of documentation to the committee) [16]. We divided the procedure into two main processes, translation and cultural adaptation.

Translation process

Two professional native Indonesian translators independently performed the forward translation from the original English version to the Indonesian language. With input from the research team, the translators reconciled differences between translations to reach a consensus and develop one synthesized Indonesian version of the AFEQT. Two independent native English translators then performed the back-translation from the Indonesian version to English. The research team then compared the back-translated version to the original English version to identify any translation errors. The translation procedures were documented by the authors.

Cultural adaptation process

The prefinal version of the Indonesian AFEQT was completed by 30 patients with documented AF. The patients were asked to complete the questionnaire and were interviewed to get their opinions about the items and responses in the questionnaire. The results were discussed among the researchers who finalized the questionnaire.

Statistical analysis

Construct validity is one of the minimum standards for PRO measurements [28]. We used a multitrait scaling analysis approach to analyze for correlations between the item and its domain. The correlation between an item and its domain is expected to be higher than the correlation between an item and other domains. For convergent and divergent validity, we used the Indonesian version of SF-36 as a comparison, since there are no other Indonesian versions of AF-specific questionnaires available at the moment. Such correlations are considered to be weak for correlation coefficients of 0.1–0.39, moderate for 0.40–0.69, strong for 0.70–0.89, and very strong for

0.90–1.00 [29]. Spearman's correlation coefficient was used to analyze the AFEQT (Indonesian version) total and domain scores and each SF-36 (Indonesian version) domain and summary measure scores.


Internal consistency and test-retest reliability were assessed to fulfill the minimum standard needed to assess the reliability of a PRO measure. Internal consistency, measured by Cronbach's α , refers to how consistent the items within a scale are and how each item measures aspects of the same underlying domain. Reports have differed on acceptable Cronbach's α values, ranging from 0.7 to 0.95 [30]. The α value is influenced by the lengths of the scale and the sample size [31]. Therefore, we considered a value of 0.70 or higher to be acceptable or ideal [28, 30, 32]. Test-retest reliability was used to evaluate the stability of the responses over time (at 1-2-week intervals) by assessing the intraclass correlation coefficient (ICC). A value of 0.5–0.75 was considered to be moderate,

0.75–0.9 was considered to be good, and higher than 0.9 was considered to be excellent stability [33]. All analyses were performed using SPSS version 22.0 (IBM) with a two-sided level of significance of 1%.

Results

Sociodemographic and medical characteristics of participants

A total of 172 AF patients visited the Cardiology Clinic from January to March 2022, of whom 133 patients met the inclusion criteria. Twelve patients were excluded due to cognitive impairment, recent hospitalization, or physical disabilities. Of 121 patients who consented to participate, 6 were excluded because of acute conditions and 13 others could not be contacted for the retest procedure, leaving 102 patients who were included in the analyses (Fig. 1). Patients who were excluded did not differ statistically from the included patients.



The mean age of participants was 58.98 ± 11.82 years. Overall, most respondents were male (52%), married (82.4%), middle school graduates (58.8%), and unemployed (71.6%). Approximately half of the participants had permanent AF (51%) and were classified as EHRA (European Heart Rhythm Association) 2a (51%). Subjects' median CHA₂DS₂-VASc [congestive heart failure, hypertension, age \geq 75, diabetes, stroke, vascular disease, age 65 to 74 and sex category (female)] score was 3, indicating a high stroke risk among participants, and 95.1% of participants received vitamin K anticoagulants

Table 1Sociodemographic and medical characteristics of 102participating AF patients

Demographics	(n = 102)
Age, years, mean (SD)	58.98
	(11.82)
Sex, n (%)	
Male	53 (52)
Female	49 (48)
BMI, median (IQR)	25.2
	(6.09)
Marital status, n (%)	
Married	84 (82.4)
Single	5 (4.9)
Widowed	13 (12.7)
Education, n (%)	
Elementary School	9 (8.8)
Middle School	60 (58.8)
Diploma	10 (9.8)
Bachelor or graduate school	23 (22.6)
Employment status, n (%)	
Government employee	3 (2.9)
Private employee	5 (4.9)
Entrepreneur	10 (9.8)
Other	11 (10.8)
Unemployed	73 (71.6)
Type of AF, n (%)	
Paroxysmal	28 (27.4)
Persistent	16 (15.7)
Longstanding persistent	6 (5.9)
Permanent	52 (51)
EHRA class, n (%)	
1	3 (2.9)
2a	52 (51)
2b	30 (29.4)
3	17 (16.7)
CHA ₂ DS ₂ -VASc score, median (IQR)	3 (2)
Ejection fraction, median (IQR)	58.35
	(16.42)
Medication history, n (%)	
Rate control only	93 (91.2)
Rhythm control only	2 (1.9)
Rate and rhythm control	5 (4.9)
VKA anticoagulants	97 (95.1)

(VKA). The sociodemographic and medical characteristics of the 102 participating AF patients are presented in Table 1. Patients took an average of 10.04 min (range 1.55 to 27.57 min; median 9.46 min) to complete the 20-item Indonesian version of the AFEQT. Around 70% of patients took more than 15 min to fill out the questionnaire and most of them were over 70 years of age.

Translation and cultural adaptation process

Item number 3 in the prefinal questionnaire led to uncertainty among 26% of patients because they actually did not have symptoms of a pause in heart activity. The research team decided not to make any revisions because the choice of words was considered to be appropriate, and was kept through the validation step to evaluate the psychometric properties of the item and the whole questionnaire.

Construct validity

Multitrait scaling analysis

All the items in the questionnaire had strong negative correlations to their own domain, and the correlation was higher compared to other domains in which the items were not assigned. A negative correlation was obtained because a scale of 1 on the questionnaire indicated no limitations/symptoms and a scale of 7 indicated the most severe limitations/symptoms, hence, the higher the scale chosen, the worse the patient's quality of life. Item number 3 had the weakest correlation in its own domain and overall score. The Multitrait Scaling Analysis is presented in Table 2.

Convergent and divergent validity

All the domains in the Indonesian AFEQT questionnaire had weak to strong positive correlations with the Indonesian version of the SF-36 questionnaire. The AFEQT Daily Activities domain had stronger correlations to SF-36 Physical Functioning, Role-Physical, Vitality domains, and PCS score compared to the SF-36 Social Functioning, Role-Emotional, Mental Health, General Health domains, and MCS score. Conversely, the AFEQT Treatment Concern domain had weaker correlations to SF-36 Physical Functioning and Role-Physical domains and PCS score, compared to the SF-36 Role-Emotional and Mental Health domains as well as MCS score. The AFEQT Symptoms domain had moderate correlations to most of the domains in SF-36, except for the Physical Functioning domain which showed a weak correlation. On the other hand, AFEQT Treatment Satisfaction domain had weak correlations to most SF-36 domains. AFEQT overall score had strong correlations to both PCS and MCS scores. The correlation between the Indonesian Version of AFEQT and SF-36 domains are presented in Table 3.

	Domains				
AFEQT	Symptoms*	Daily Activities*	Treatment Concern*	Treatment Satisfaction*	Overall
Items					Score*
Symptoms					
1	-0.818	-0.512	-0.543	-0.410	-0.652
2	-0.858	-0.629	-0.597	-0.489	-0.740
3	-0.639	-0.413	-0.470	-0.392	-0.526
4	-0.749	-0.570	-0.454	-0.354	-0.652
Daily Activities					
5	-0.649	-0.820	-0.647	-0.333	-0.828
6	-0.594	-0.727	-0.572	-0.334	-0.734
7	-0.630	-0.873	-0.553	-0.440	-0.823
8	-0.671	-0.829	-0.490	-0.481	-0.794
9	-0.594	-0.843	-0.551	-0.372	-0.797
10	-0.607	-0.869	-0.494	-0.519	-0.796
11	-0.584	-0.869	-0.430	-0.498	-0.765
12	-0.481	-0.820	-0.356	-0.435	-0.678
Treatment Concern					
13	-0.686	-0.529	-0.780	-0.398	-0.712
14	-0.622	-0.469	-0.808	-0.327	-0.666
15	-0.526	-0.514	-0.807	-0.387	-0.696
16	-0.468	-0.392	-0.841	-0.394	-0.618
17	-0.456	-0.432	-0.788	-0.351	-0.639
18	-0.495	-0.412	-0.813	-0.462	-0.623
Treatment Satisfaction					
19	-0.452	-0.460	-0.413	-0.914	-0.502
20	-0.561	-0.498	-0.439	-0.960	-0.551

Table 2 The Multitrait Scaling Analysis Approach

*Correlation is significant at the 0.01 level (two-tailed). Bolded numbers indicate number of items allocated to each domain. The Treatment Satisfaction domain was not included in Overall Score analysis

Table 3 Correlation between the Indonesian version of AFEQT and SF-36 domains

AFEQT	SF-36									
Domains	Domains					Components				
	PF*	RP*	BP*	GH*	VT*	SF*	RE*	MH*	PCS*	MCS*
Symptoms	0.372	0.528	0.503	0.498	0.561	0.443	0.466	0.570	0.548	0.621
Daily Activities	0.617	0.677	0.603	0.524	0.693	0.415	0.517	0.561	0.746	0.681
Treatment Concern	0.430	0.483	0.372	0.480	0.532	0.493	0.494	0.569	0.539	0.649
Treatment Satisfaction	0.338	0.387	0.358	0.521	0.455	0.345	0.338	0.386	0.453	0.467
Overall Score	0.586	0.667	0.574	0.558	0.693	0.498	0.574	0.634	0.730	0.746

*Correlation is significant at the 0.01 level (two-tailed). Bolded numbers indicate correlations in the AFEQT and SF-36 domains which have similar types of questions The Treatment Satisfaction domain was not included in Overall Score analysis

Reliability

Cronbach's α was 0.947 for the overall Indonesian version of AFEQT and as follows for the four domains: Symptoms (0.818), Daily Activities (0.943), Treatment Concern (0.894), and Treatment Satisfaction (0.865). All these values indicated acceptable or ideal internal consistency [30, 32]. The ICCs, indicators of test-retest reliability, were considered good for overall score (0.862), Symptoms (0.791), Daily Activities (0.842), and Treatment Concern (0.824), and moderate for the Treatment Satisfaction domain (0.715). However, at the item level, only 50% of items had ICC>0.75, while the others had ICC 0.5–0.75. The reliability analysis is presented in Tables 4 and 5.

Discussion

Quantifying patients' perceptions by measuring their HRQoL is an important measure to evaluate treatment success and improve patient care [1]. Patients with AF mostly have impaired QoL, independent of other cardiovascular conditions, because they experience a variety of symptoms [5]. Compared to other AF-specific instruments, AFEQT is more comprehensive in capturing the disease and its management impact on patients' physical

Table 4 The ICC of items in the Indonesian version of AFEQT

Item	ICC (95%CI)
Symptoms	
1	0.790 (0.687–0.858)
2	0.742 (0.613-0.828)
3	0.604 (0.414-0.732)
4	0.719 (0.585–0.810)
Daily Activities	
5	0.668 (0.509–0.776)
6	0.681 (0.527-0.784)
7	0.760 (0.646-0.838)
8	0.767 (0.656-0.843)
9	0.774 (0.667-0.847)
10	0.776 (0.668-0.849)
11	0.815 (0.726–0.875)
12	0.763 (0.648-0.840)
Treatment Concern	
13	0.788 (0.687–0.857)
14	0.828 (0.744-0.884)
15	0.715 (0.579–0.807)
16	0.724 (0.592-0.813)
17	0.781 (0.643-0.861)
18	0.640 (0467-0.757)
Treatment Satisfaction	
19	0.521 (0.296–0.675)
20	0.734 (0.607–0.820)

The freatment satisfaction domain was not included in Overali score analysis

Table 5 The cronbach's α coefficient and ICC of the Indonesian version of the AFEQTTable caption

AFEQT Domains	Cronbach's α	ICC (95%CI)
Symptoms	0.818	0.791 (0.683–0.861)
Daily Activities	0.943	0.842 (0.766–0.893)
Treatment Concern	0.894	0.824 (0.733–0.884)
Treatment Satisfaction	0.865	0.715 (0.578–0.807)
Overall Score	0.947	0.862 (0.792–0.908)

and emotional function. It has also been used in many large-scale clinical and observational studies on the quality of life in AF patients [6, 23, 34–36]. However, before the original English version can be used in non-Englishspeaking populations, the questionnaire must undergo translation as well as cultural adaptation and validation to ensure that it has the same objective, properties, and function as the original questionnaire. We translated the AFEQT into the Indonesian language and established its psychometric properties in Indonesian AF patients.

For the translation and cultural adaptation processes, we used a guideline developed by Beaton et al. This guideline has a similar outline to the one published by the ISPOR task force, which consists of forward translation, synthesis into one forward translation (reconciliation), back translation, expert committee review (back translation review), and test of the prefinal version in a small group of relevant patients (cognitive debriefing) [16]. We did not perform harmonization to compare the back translation of multiple language versions with each other due to lack of data of the other language versions.

The baseline characteristics of participants in terms of educational background and employment status were quite different from the original study in the US, in which the majority of participants were full-time or part-time workers and had college educational backgrounds. These differences might have affected patients' understanding of the questionnaire and raised the question of whether this questionnaire was applicable to populations with different academic backgrounds and employment statuses. However, the characteristics of gender, marital status, educational background, and employment status in our study were somewhat similar to the adaptation studies in Turkey and China, in which most participants had at least secondary education and were unemployed [11, 12]. Thus, a translated AFEQT questionnaire could also be implemented in Indonesia. Moreover, the results showed that the Indonesian version of AFEQT was highly comparable with psychometric properties reported in the original version and adapted versions, such as those in Russian, Greek, Turkish, and Chinese [9, 11–14].

Content validity, construct validity, and responsiveness are considered to be the minimum standards for a PRO measure [28]. However, since our study objective was to validate the adapted version of the established AFEQT, we did not assess the content validity. Responsiveness was not assessed since that would need a longitudinal study. Therefore, we assessed construct validity in our study (multitrait scaling analysis, convergent and divergent validity) to measure the expected association against other instruments which measure the same construct [28].

Our results showed that the Indonesian version of AFEQT had an appropriate construct validity by demonstrating an adequate multitrait scaling analysis as well as convergent and divergent correlations to the Indonesian version of SF-36. In multitrait scaling analysis, all the items had higher correlations to the domain they were assigned to compared to other domains. Item number 3 in the Indonesian version of AFEQT had the lowest correlation, both to its domain and overall score. 26% of participants in the prefinal testing stage exhibited poor understanding of the question. This finding was also supported by a Chinese study in which item 3 had the lowest factor loading compared to other items [12] Therefore, item 3 is a cause of concern for the future use of the questionnaire. For convergent and divergent validity, the overall score of the Indonesian AFEQT showed a moderate-to-strong correlation with all domains in the Indonesian version of SF-36. The AFEQT Daily Activities domain correlated well with the physical component (PCS) of SF-36, while the Treatment Concern domain

correlated better with the mental component (MCS) of SF-36 compared to the physical component. These results were similar to the original AFEQT study by Spertus et al. [9]. However, the Symptom domain had a weak correlation to the Physical Functioning domain in SF-36. Patients' impaired functional status is not solely due to AF symptoms and is more influenced by cardiovascular conditions and other risk factors for AF, such as age and gender [37]. Moreover, permanent AF patients predominated our sample; they tend to have a lower symptom burden than patients with other types of AF. On the other hand, the Treatment Satisfaction domain showed a weak correlation to almost all domains in SF-36. This finding was predictable because two satisfaction items do not assess patient health status and were not included in the overall score. Satisfaction items did not have a potential criterion standard to which they could be compared [9]. However, evaluating patient treatment satisfaction is also one of the main characteristics of patient-reported outcomes [38].

In terms of reliability, the Indonesian version of the AFEQT was also shown to be an internally reliable instrument with satisfactory stability, as indicated by the very high Cronbach's α and ICC for overall score (0.947 and 0.862, respectively). These findings were similar to AFEQT validity studies in Russia, Greece, Turkey, and China, which also had satisfactory questionnaire reliability [11-14]. However, for the ICC, we used a value of 0.75 or greater to indicate good test-retest reliability. This cut-off value was higher than that used in other AFEQT validation studies. Therefore, one domain (Treatment Satisfaction) and half of the items did not meet the criteria of good test-retest reliability. The lowest ICC value was in item number 19 (0.521), followed by item numbers 3 (0.604) and 18 (0.640). This slightly lower value may be attributable to the nature of AF patients who have a quite wide range of symptoms, from asymptomatic and unaware of any treatment for their AF to some debilitating symptoms. The low degree of measurement agreement also contributed to the low ICC [33]. However, ICC analysis at the domain level indicated good test-retest reliability.

This study had several limitations. First, we did not reassess the content validity of the questionnaire. Second, this study was a single-center study with a relatively small sample size compared to the original AFEQT validation study. Third, our sample did not adequately represent AF type, as more than 50% of our subjects had permanent AF. However, this characteristic was not expected to influence the psychometric properties of the questionnaire. Fourth, we did not evaluate the responsiveness of the tool in terms of the ability to detect clinically significant changes in patient health status over time. Further research is needed to evaluate the responsiveness of the Indonesian version in different health settings. Finally, due to the absence of other AF-specific validated questionnaires, we used a generic instrument (SF-36) for convergent and divergent validation, which may not have been able to capture AF-specific symptoms.

Conclusions

The Indonesian version of the AFEQT was deemed valid, reliable, and comparable to the original English and the other translated versions. Use of the Indonesian AFEQT in clinical settings could further enable health professionals to evaluate patient QOL with regards to AF and treatment, as well as to gain a thorough understanding of how to best give patient-centered care. However, a multicenter study with a longer observation is needed to assess the responsiveness of the Indonesian version of the AFEQT.

Abbreviations

AF	Atrial Fibrillation
AFEQT	Atrial Fibrillation Effect on Quality-of-life
BP	Bodily Pain
CAD	Coronary Artery Disease
CHA ₂ DS ₂ -VASc	Congestive heart failure, Hypertension, Age ≥ 75, Diabetes, Stroke Vascular disease, Age 65 to 74 and Sex category (female)
CKD	Chronic Kidney Disease
EHRA	European Heart Rhythm Association
GH	General Health
HF	Heart Failure
HRQoL	Health-related Quality of Life
ICC	Intraclass correlation coefficient
MCS	Mental Component Summary
MH	Mental Health
OSA	Obstructive Sleep Apnea
PCS	Physical Component Summary
PF	Physical Functioning
PRO	Patient-Reported Outcomes
QoL	Quality of Life
RE	Role-Emotional
RP	Role-Physical
SF	Social Functioning
SF-36	the 36-item Short Form Survey
SPSS	Statistical Package for Social Sciences
VT	Vitality

Acknowledgements

We would like to express our gratitude to our advisors, Kuntjoro Harimurti, Rr. Dyah Purnamasari, Ikhwan Rinaldi, Ika Prasetya Wijaya, Wismandari Wisnu, and Pringgodigdo Nugroho, who gave constructive inputs throughout this project.

Author contributions

Conceptualization: M.Y., P.Z., M.M., and S.S.; Methodology: M.Y., M.M., and J.K.; Data: M.Y., P.Z., and S.S.; Analysis: M.Y., P.Z., M.M., and J.K.; Writing the manuscript: M.Y., P.Z., and M.M.; Critical revision: M.Y., M.M., and J.K.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Data availability

The dataset used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Since human subjects were involved in this study, research ethics committee of the Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital reviewed and approved the study protocol, with approval number KET-1054/UN2.F1/ETIK/PPM.00.02/2021. Participating patients signed an informed consent provided by the Ethics Committee.

Consent for publication

Not Applicable.

Competing interests

The authors declare no conflict of interest in this study.

Author details

¹Department of Internal Medicine, dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

²Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, National General Hospital, Universitas Indonesia, Jakarta, Indonesia

³Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, National General Hospital, Universitas Indonesia, Jakarta, Indonesia

Received: 22 June 2023 / Accepted: 6 December 2023 Published online: 15 December 2023

References

- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J 42(5):373–498
- Wong CX, Brown A, Tse HF, Albert CM, Kalman JM, Marwick TH et al (2017) Epidemiology of Atrial Fibrillation: The Australian and Asia-Pacific Perspective. Hear Lung Circ. 26(9):870–9. https://doi.org/10.1016/j.hlc.2017.05.120
- Yuniadi Y, Hanafy DA, Rahardjo SB, Tondas AE, Maharani E, Hermanto DY et al (2015) 2014 Indonesian Heart Association Guidelines of Management of Atrial Fibrillation. Indones J Cardiol 35(2):102–133
- Amir M, Irwan, Syafaryuni M, Levina (2021) Prevalence and characteristics of atrial fibrillation in Makassar city population: A telemedicine study. Gac Sanit. 35:S510–4. https://doi.org/10.1016/j.gaceta.2021.10.082
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962
- Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ et al (2015) Association between Atrial Fibrillation Symptoms, Quality of Life, and patient outcomes: results from the outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 8(4):393–402
- Rumsfeld JS, Alexander KP, Goff DC, Graham MM, Ho PM, Masoudi FA et al (2013) Cardiovascular health: the importance of measuring patient-reported health status a scientific statement from the American heart association. Circulation 127(22):2233–2249
- Aliot E, Botto GL, Crijns HJ, Kirchhof P (2014) Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace 16(6):787–796
- Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR et al (2011) Development and validation of the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire in patients with Atrial Fibrillation. Circ Arrhythmia Electrophysiol 4(1):15–25
- ePROVIDE Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT). [cited 2021 Aug 11]. Available from: https://eprovide.mapi-trust.org/instruments/ atrial-fibrillation-effect-on-quality-of-life
- Günes F, Boyraz S (2021) Effect of atrial fibrillation on quality of life (AFEQT) questionnaire: a Turkish validity and reliability study. Turk Kardiyol Dern Ars 49(3):223–232

- Li PWC, Yu DSF, Yan BP (2021) Psychometric validation of the Chinese Version of Atrial Fibrillation Effect on Quality-of-life questionnaire among Chinese patients. J Cardiovasc Nurs 36(2):136–142
- Sychov OS, Borodai AO, Borodai ES, Romanyuk PB, Mikhaleva TV, Sribna OV (2016) Validation of the Russian version of the Atrial Fibrillation Effect on QualiTy-of-life questionnaire in patients with non valvular atrial fibrillation and flutter. Ukr J Cardiol 4:97–106
- Tailachidis P, Tsimtsiou Z, Galanis P, Theodorou M, Kouvelas D, Athanasakis K et al (2016) The atrial fibrillation effect on quality-of-life (AFEQT) questionnaire: Cultural adaptation and validation of the Greek version. Hippokratia 20(4):264–267
- Wild D, Grove A, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P (2005) Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Heal. 8(2):94–104. Available from: http://www.ispor.org
- Beaton DE, Bombardier C, Guillemin F, Ferraz MB (2000) Guidelines for the process of Cross Cultural Adaptation of Self-Report measures. Spine (Phila Pa 1976) 25(24):3186–3191
- 17. Guillemin F (1995) Cross-cultural adaptation and validation of heatth status measures. Scand J Rheumatol 24(2):61-63
- Salim S, Yamin M, Alwi I, Setiati S (2017) Validity and reliability of the Indonesian Version of SF-36 Quality of Life Questionnaire on patients with Permanent pacemakers. Acta Med Indones 49(1):10–16
- Yamin M, Salim S, Setiati S, Alwi I, Zulmiyusrini P (2019) Cross-cultural adaptation and validation of the Indonesian version of AQUAREL on patients with permanent pacemaker: A cross-sectional study. BMC Res Notes. 12(1):10–5. https://doi.org/10.1186/s13104-019-4208-1
- Jenkins LS, Brodsky M, Schron E, Chung M, Rocco TJ, Lader E et al (2005) Quality of life in atrial fibrillation: the Atrial Fibrillation follow-up investigation of Rhythm Management (AFFIRM) study. Am Heart J 149(1):112–120
- Kim YG, Shim J, Choi J, II, Kim YH (2016) Radiofrequency catheter ablation improves the quality of life measured with a short form-36 questionnaire in atrial fibrillation patients: a systematic review and meta-analysis. PLoS ONE 11(9):1–22
- 22. Thrall G, Lane D, Carroll D, Lip GYH (2006) Quality of life in patients with Atrial Fibrillation: a systematic review. Am J Med. ;119(5)
- Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH et al (2019) Effect of catheter ablation vs Medical Therapy on Quality of Life among patients with Atrial Fibrillation: the CABANA Randomized Clinical Trial. JAMA -J Am Med Assoc 321(13):1275–1285
- 24. Groenveld HF, Van Den Crijns HJGM, Van Sonderen E, Alings AM, Tijssen JGP et al (2011) The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the race II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 58(17):1795–1803
- Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JGP et al (2004) Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: Results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol. 43(2):241–7. https://doi.org/10.1016/j. jacc.2003.08.037
- 26. Ware J Jr, Gandek B (1998) Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 51(11):903–912
- RAND. 36-Item Short Form Survey (SF-36) Scoring Instructions. 1992 [cited 2023 May 3]. Available from: https://www.rand.org/health-care/surveys_ tools/mos/36-item-short-form/scoring.html
- Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF et al (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22(8):1889–1905
- 29. Schober P, Schwarte LA (2018) Correlation coefficients: appropriate use and interpretation. Anesth Analg 126(5):1763–1768
- de Souza AC, Alexandre NMC, de Guirardello E (2017) Propriedades psicométricas na avaliação de instrumentos: avaliação da confiabilidade e da validade. Epidemiol E Serv Saude Rev do Sist Unico Saude do Bras 26(3):649–659
- Streiner DL, Norman GR, Cairney J (2015) Health Measurement Scales: a practical guide to their development and use, 5th edn. Oxford University Press, New York
- 32. Tavakol M, Dennick R (2011) Making sense of Cronbach's alpha. Int J Med Educ 2:53–55

- Koo TK, Li MY (2016) A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 15(2):155–63. https://doi.org/10.1016/j.jcm.2016.02.012
- Pavlovic N, Kuniss M, Velagic V, Hermida JS, Healey S, Arena G et al (2021) Impact of initial rhythm control with cryoballoon ablation versus drug therapy on atrial fibrillation recurrence and quality of life: results from the Cryo-FIRST study. EP Eur 23(Supplement3):236–237
- Ikemura N, Spertus JA, Kimura T, Mahaffey K, Piccini JP, Inohara T et al (2019) Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation - Keio Interhospital Cardiovascular studies-atrial fibrillation (KiCS-AF). BMJ Open 9(12):1–9
- Ha AC, Labos C, Dorian P, Mancini GBJ, Cox JL, Gladstone DJ et al (2019) Factors Associated with changes in Quality of Life among Atrial Fibrillation patients in Real-World Clinical Practice: findings from the prospective

Canadian SPRINT-AF Registry [Abstract]. Circ Arrhythmia Electrophysiol. ;140(Suppl_1).

- Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF et al (2012) Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation 125(23):2933–2943
- Cella D, Hahn EA, Jensen SE, Butt Z, Nowinski CJ, Rothrock N et al (2015) Patient-reported outcomes in performance measurement. RTI Press, New York

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.